Home / Market News / $CRBP
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

Mizuho Lowers Price Target on Corbus Pharmaceuticals to $23

Nov 13, 2026, 2:16 PM UTC · Primary ticker $CRBP

Mizuho Securities analyst Graig Suvannavejh adjusted Corbus Pharmaceuticals' price target to $23 from $24, while maintaining an Outperform rating. This minor adjustment reflects a broader trend of target price revisions for the company in 2026, following recent third-quarter financial results.

Mizuho Securities analyst Graig Suvannavejh lowered the price target for Corbus Pharmaceuticals (CRBP) from $24 to $23, while keeping an 'Outperform' rating. This adjustment is a relatively minor change and is part of a broader trend of target price revisions for the company, likely influenced by its recent third-quarter financial results. For traders, this indicates a slight recalibration of expectations by an analyst, but the maintained 'Outperform' rating suggests continued confidence in the company's long-term prospects. The short-term impact is likely minimal, as the change is small and the rating remains positive, but it could contribute to a slightly cautious sentiment among investors. The key risk is if other analysts follow suit with more significant downgrades, or if the underlying reasons for the target revision point to deeper issues not fully disclosed in this brief filing.

$CRBP neutral Price target lowered but Outperform rating maintained
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.